Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has released a presentation by its CEO at the Annual General Meeting, highlighting the progress of its drug narmafotinib (AMP945), a FAK inhibitor showing promise in preclinical cancer studies. The ACCENT trial is currently assessing the drug’s efficacy in combination with other treatments for pancreatic cancer, with the trial being conducted across sites in Australia and South Korea.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK also plays a role in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 7,121,802
Technical Sentiment Signal: Buy
Current Market Cap: A$92.43M
See more data about ATX stock on TipRanks’ Stock Analysis page.